These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 23733447)

  • 21. AIDS dementia complex: response to highly active antiretroviral therapy.
    Maddocks S; Iredell J
    AIDS; 1999 Dec; 13(17):2490-1. PubMed ID: 10597800
    [No Abstract]   [Full Text] [Related]  

  • 22. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.
    Strain MC; Letendre S; Pillai SK; Russell T; Ignacio CC; Günthard HF; Good B; Smith DM; Wolinsky SM; Furtado M; Marquie-Beck J; Durelle J; Grant I; Richman DD; Marcotte T; McCutchan JA; Ellis RJ; Wong JK
    J Virol; 2005 Feb; 79(3):1772-88. PubMed ID: 15650202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV, antiretroviral therapies, and the brain.
    Liner KJ; Ro MJ; Robertson KR
    Curr HIV/AIDS Rep; 2010 May; 7(2):85-91. PubMed ID: 20425562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changing clinical phenotypes of HIV-associated neurocognitive disorders.
    Sacktor N
    J Neurovirol; 2018 Apr; 24(2):141-145. PubMed ID: 28752495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating HIV Infection in the Central Nervous System.
    Calcagno A; Di Perri G; Bonora S
    Drugs; 2017 Feb; 77(2):145-157. PubMed ID: 28070871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.
    Clark US; Cohen RA
    Curr Opin Investig Drugs; 2010 Aug; 11(8):884-900. PubMed ID: 20721831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury.
    Yuan NY; Kaul M
    J Neuroimmune Pharmacol; 2021 Mar; 16(1):90-112. PubMed ID: 31385157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment.
    Spudich S; González-Scarano F
    Cold Spring Harb Perspect Med; 2012 Jun; 2(6):a007120. PubMed ID: 22675662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Could differential virological characteristics account for ongoing viral replication and insidious damage of the brain during HIV 1 infection of the central nervous system?
    Vissers M; Stelma FF; Koopmans PP
    J Clin Virol; 2010 Dec; 49(4):231-8. PubMed ID: 20833583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human immunodeficiency virus-associated dementia.
    Clifford DB
    Arch Neurol; 2000 Mar; 57(3):321-4. PubMed ID: 10714656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV encephalitis despite suppressed viraemia: a case of compartmentalized viral escape.
    Bingham R; Ahmed N; Rangi P; Johnson M; Tyrer M; Green J
    Int J STD AIDS; 2011 Oct; 22(10):608-9. PubMed ID: 21998185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical implications of HIV-1 drug resistance in the neurological compartment.
    Antinori A; Cingolani A; Giancola ML; Forbici F; De Luca A; Perno CF
    Scand J Infect Dis Suppl; 2003; 106():41-4. PubMed ID: 15000582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CNS Neurotoxicity of Antiretrovirals.
    Lanman T; Letendre S; Ma Q; Bang A; Ellis R
    J Neuroimmune Pharmacol; 2021 Mar; 16(1):130-143. PubMed ID: 31823251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic approaches to HIV-associated neurocognitive disorders.
    Avedissian SN; Dyavar SR; Fox HS; Fletcher CV
    Curr Opin Pharmacol; 2020 Oct; 54():102-108. PubMed ID: 33049585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interventions for Neurocognitive Dysfunction.
    Ellero J; Lubomski M; Brew B
    Curr HIV/AIDS Rep; 2017 Feb; 14(1):8-16. PubMed ID: 28110422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
    Wright EJ
    Curr Opin HIV AIDS; 2009 Sep; 4(5):447-52. PubMed ID: 20048710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global Perspective of Novel Therapeutic Strategies for the Management of NeuroAIDS.
    Kumar S; Maurya VK; Dandu HR; Bhatt ML; Saxena SK
    Biomol Concepts; 2018 May; 9(1):33-42. PubMed ID: 29742062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose.
    Calcagno A; Barco A; Trunfio M; Bonora S
    Curr HIV/AIDS Rep; 2018 Feb; 15(1):84-91. PubMed ID: 29363025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurocognitive disorders seen in HIV disease.
    Ungvarski PJ; Trzcianowska H
    Issues Ment Health Nurs; 2000; 21(1):51-70. PubMed ID: 10839052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.